Posted on 27/07/2010 in Pharmaceutical Company Financials Alcon has responded positively to its second quarter financial performance after announcing better-than-expected results during the three-month period.
In the firm's latest quarterly fiscal report, Alcon revealed that its adjusted earnings per share for the quarter stood at $2.22 (1.43 pounds), a year-on-year increase of 14.4 per cent.
According to the company, this increase in earnings was driven by an 11.3 per cent rise in organic sales, with its glaucoma and intraocular lens divisions cited as key drivers of this improvement.
Thomas Plaskett, chairman of the Alcon Independent Director Committee, also pointed to the firm's recent acquisition of LenSx Lasers as a move which will drive future growth, adding that Alcon has increased its earnings guidance for the full year.
He said: "These latest results highlight the fact that Alcon's underlying business fundamentals continue to build upon the momentum of previous quarters."
Next month, Alcon will be voting on the conditional election of new company directors as part of ongoing negotiations with Novartis, which would see the latter firm purchase shares in Alcon. Other news stories from 27/07/2010
Read more in the Zenopa News Archive
How this news is generated
|
